Simtra BioPharma Solutions Revenue and Competitors
Estimated Revenue & Valuation
- Simtra BioPharma Solutions's estimated annual revenue is currently $91.1M per year.
- Simtra BioPharma Solutions's estimated revenue per employee is $137,959
Employee Data
- Simtra BioPharma Solutions has 660 Employees.
- Simtra BioPharma Solutions grew their employee count by 36% last year.
Simtra BioPharma Solutions's People
Name | Title | Email/Phone |
---|
Simtra BioPharma Solutions Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.6M | 23 | 0% | N/A | N/A |
#2 | $23.5M | 117 | -28% | N/A | N/A |
#3 | $575.7M | 2864 | 2% | N/A | N/A |
#4 | $1.8M | 18 | -10% | $1.5M | N/A |
#5 | $5.8M | 29 | -6% | N/A | N/A |
#6 | $10.7M | 53 | 15% | N/A | N/A |
#7 | $271.4M | 1350 | 4% | N/A | N/A |
#8 | $9.2M | 46 | 10% | N/A | N/A |
#9 | $27760M | 44397 | 4% | N/A | N/A |
#10 | $1.2M | 6 | -54% | N/A | N/A |
What Is Simtra BioPharma Solutions?
As a premier, independently owned CDMO with over 65 years of sterile injectable manufacturing experience, Simtra BioPharma Solutions offers world-class cGMP sterile fill/finish, technical expertise, quality service, and a uniquely collaborative approach. Pharmaceutical and biotech companies partner with us when they face formulation challenges, clinical supply hurdles, surges in demand due to market fluctuations, or risk mitigation concerns. Our teams are driven to offer our clients tailored and versatile solutions to help them bring their products to market so they can get to the patients who need them.\n(Simtra is a tradename of Baxter Oncology GmbH and Baxter Pharmaceutical LLC)
keywords:N/AN/A
Total Funding
660
Number of Employees
$91.1M
Revenue (est)
36%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $119.6M | 660 | -8% | N/A |
#2 | $75M | 663 | 9% | N/A |
#3 | $135.3M | 664 | 12% | N/A |
#4 | $205.3M | 676 | -1% | N/A |
#5 | $288.7M | 711 | 5% | N/A |